Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease

Next Previous
X
Search
Trial Profile

A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pimavanserin (Primary)
  • Indications Parkinson's disease; Psychotic disorders
  • Focus Registrational; Therapeutic Use
  • Sponsors Acadia Pharmaceuticals

    • Most Recent Events

    • 18 Sep 2022 Results of pooled analysis of 3 6-week studies (012, 014, and 020) and subgroup of PD dementia (PDD) patients from HARMONY assessing motor and cognition-related safety in pimavanserin-treated patients with Parkinson's Disease Psychosis, presented at the 26th International Congress of Parkinson's Disease and Movement Disorders.
    • 14 May 2022 Results from a pooled analysis of three 6-week studies (012, 014, and 020) and subgroup of patients with PD dementia from HARMONY presented at the 2022 Annual Scientific Meeting of the American Geriatrics Society
    • 11 Mar 2015 According to ACADIA Pharmaceuticals media release, NDA submission for pimavanserin to US FDA is likely to take place in second half of 2015; data from this trial will support regulatory submission.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top